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Inhibition of cell cycle progression by dual phosphatidylinositol-
3-kinase and mTOR blockade in cyclin D2 positive multiple
myeloma bearing IgH translocations
J Glassford, D Kassen, J Quinn, C Stengel, K Kallinikou, A Khwaja and KL Yong
Multiple myeloma (MM) is a clinically and genetically heterogenous cancer where tumour cells have dysregulated expression of
a D-type cyclin, often in association with a recurrent IgH translocation. Patients whose tumour cells express cyclin D2, with the
translocation t(4;14) or t(14;16), generally have more proliferative disease and inferior outcomes. The phosphatidylinositol-3-
kinase (PI3K) pathway is a major regulator of D-type cyclin expression and cell cycle entry. We evaluated the effect of PI3K
pathway blockade on cell cycle behaviour in MM cells, investigating differences between cyclin D2- and cyclin D1-expressing
tumours. MM cell lines and primary bone marrow CD138
þ MM cells were exposed to the pan-PI3K/mTOR inhibitor, PI-103, and
assessed for cell cycle proﬁles, [
3H]-thymidine uptake and cell cycle proteins. We report, in both cell lines and primary MM cells,
that PI-103 induced cell cycle arrest with downregulation of cyclin D2 and CDK4/6 in MM cells expressing cyclin D2 via t(4;14)
or t(14;16) translocations. Cells expressing cyclin D1 via t(11;14) were insensitive to PI-103, despite exhibiting inhibition of
downstream signalling targets. In primary MM cells, PI-103 enhanced the anti-proliferative effects of anti-MM agents. Treatment
paradigms including blockade of the PI3K/mTOR pathway should be targeted at patients with IgH translocations associated
with cyclin D2 overexpression.
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INTRODUCTION
Multiple myeloma (MM) is the second most common haemato-
poietic cancer and is caused by an accumulation of malignant
plasma cells in the bone marrow. Although the recent use of
proteasome inhibitors and IMiDs have improved response rates
and overall survival, this cancer remains incurable in the vast
majority of patients and new treatments are urgently needed. We
now understand that the considerable clinical heterogeneity
corresponds to different biological subtypes that are underpinned
by distinct genetic changes.
1,2 This poses a great challenge to
the development of effective therapies, as responses to novel
therapies may vary depending upon the biological subtype of
disease. A subgroup of patients have inferior outcomes: poor
response rates, shorter response duration and overall survival.
3
Despite some evidence of improved responses to novel agents, a
signiﬁcant unmet need remains for such patients. Importantly,
these patients fall into identiﬁable subgroups based on particular
genetic lesions and expression proﬁles. The translocation/cyclin D
classiﬁcation is based on dysregulation of a D-type cyclin, together
with the presence of a recurrent translocation that places an
oncogene under the control of the strong IgH enhancer. This
classiﬁcation is validated by distinct expression proﬁles and by
notable differences in clinical features and outcome.
1,4,5 Patients
whose tumour cells carry the t(4;14) involving the FGFR3/MMSET
genes and the t(14;16) or t(14;20) involving the maf oncogene, fall
into subgroups with inferior outcomes.
3 This subtype of disease
has a more proliferative proﬁle and is associated with dysregu-
lated expression of cyclin D2, which is the major D-type cyclin
expressed by B-lineage cells, regulating cell cycle entry in B-cell
development and activation. Unlike normal plasma cells that have
irreversibly exited the cell cycle, MM cells retain the capacity for
self-renewal, and higher proliferative rates signify a worse
outcome.
6 Thus, anti-proliferative therapies aimed at disrupting
the cellular networks that control cell cycle entry may hold the key
to more effective treatments in these patient subgroups.
Until recently, however, the mechanisms responsible for
mediating cell cycle entry in primary MM cells were not known.
We recently showed, for the ﬁrst time, that MM cells from patients
with t(4;14) and t(14;16) respond to mitogenic growth factors with
upregulation of cyclin D2, CDK4 and 6, leading to retinoblastoma
protein (pRb) phosphorylation and cell cycle entry/progression,
thus providing functional validation for the observed D-type cyclin
dysregulation in this disease.
7,8 In contrast, MM cells with t(11;14)
disease characterized by overexpression of cyclin D1 were less
dependent on exogenous stimuli for cell cycle progression.
The phosphatidylinositol-3-kinase (PI3K) pathway is an impor-
tant target in cancer, as it activates the Akt/Protein kinase B
signalling cascade that phosphorylates a number of target
molecules to regulate cell growth, proliferation and survival.
9
This pathway mediates the effects of major MM growth factors,
such as insulin-like growth factor-I (IGF-I) and interleukin-6 (IL-6)
that stimulate proliferation, survival and drug resistance.
10
The PI3K pathway is essential for activation of D-type cyclins
and subsequent cell cycle entry in normal B lymphocytes.
11
There is evidence for activation of the PI3K/Akt pathway in
MM. Phosphorylation of Akt has been demonstrated in bone
marrow biopsies from MM patients,
12 whereas PI3K signalling is
activated in response to agents that promote survival, and/or
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factor)/APRIL (A proliferation-inducing ligand), and adhesion to
extracellular matrix.
12 In addition, PI3K signalling may be activated
by loss of the negative regulator, PTEN, as evidenced in some MM
cell lines, or by Ras mutations, present in about 20% of MM
tumours.
13 Although early experience with pan-PI3K inhibitors
resulted in toxicity to normal tissues in preclinical models, the
recent development of isoform-speciﬁc compounds with lower
toxicity proﬁles has led to renewed interest in this pathway as a
target for anti-cancer therapies. One of the key targets of the PI3K/
Akt pathway is mTOR, and feedback signalling from mTOR
inhibition (for example, by rapalogs) can lead to PI3K activation
thereby attenuating therapeutic effects
14 providing the rationale
for employing dual PI3K/mTOR inhibitors.
The aim of this work was to deﬁne the effect of dual inhibition
of PI3K/mTOR signalling on cell cycle progression and regulatory
proteins in MM and to explore differences between different
subgroups. PI-103 is a potent and selective inhibitor of class I PI3Ks
and mTOR, that blocks proliferation of several solid tumour cell
lines and shows therapeutic activity towards human solid tumour
xenografts.
15 We hypothesized that, because of aberrant expres-
sion of cyclin D2 and reliance on mitogen-activated pathways, MM
cells bearing t(4;14) and t(14;16) would be especially vulnerable to
PI-103.
MATERIALS AND METHODS
Cell lines
The KMS11, KMS12BM, KMS21BM, KMS26, KMS27 and KMS28PE cell lines
were donated by Dr T Otsuki, (Kawasaki Medical School, Okayama, Japan)
and MM1-S by Dr S Rosen (Northwestern University, Chicago, IL, USA).
Other myeloma cell lines (OPM2, NCI-H929, U266, JIM1 and LP1) were
obtained from ATCC. Cells were passaged in RPMI-1640 containing
2m ML -glutamine, 100units/ml penicillin/streptomycin and 10% foetal
calf serum (FCS). For IGF-I stimulation experiments, cells were washed in
phosphate-buffered saline and seeded at 5 10
5 cells/ml in RPMI-1640
containing 2mML-glutamine and 100units/ml penicillin/streptomycin, with
or without 10% FCS or 100ng/ml rhIGF-I (R&D Systems, Abingdon, Oxford,
UK). PI-103-HCl (Tocris Bioscience, Bristol, UK) was prepared in 1mM DMSO
and diluted to a ﬁnal concentration of 0.125- -2mM in culture medium.
Control cultures were treated with an equivalent amount of DMSO.
Primary samples
BM aspirates and peripheral blood samples were obtained from MM
patients after informed consent and with full ethical approval from an
institutional review board. CD138
þ plasma cells were isolated from BM
aspirates or peripheral blood using MACS CD138 MicroBeads (Miltenyi
Biotec, Bisley, Surrey, UK); purity of malignant cells was 490%. Samples
were cultured as described for human multiple myeloma cell lines (HMCL)
or snap frozen and stored at - -801C before analysis by western blotting.
Cell proliferation/viability analysis
Cell viability following PI-103 treatment of HMCL was performed using
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium (MTS) assay (CellTiter 96 AQueous Assay; Promega,
Southampton, UK). Cells were cultured in triplicate at 10
5 cells/well and
analysed according to the manufacturer’s instructions.
Cell proliferation was monitored by [
3H]-thymidine incorporation. Cells
were cultured in triplicate at 10
5 cells/well, and 1mCi of [
3H]-thymidine was
added for the ﬁnal 4h of the indicated culture period. Cells were harvested
using an automated cell harvester and [
3H]-thymidine incorporation into
DNA was quantiﬁed using a scintillant sheet and counter (Meltilex; Wallac,
Turku, Finland). Data presented are mean counts per minute±s.d.
Flow cytometric analysis
Cell cycle analyses were performed by propidium iodide staining for
DNA content and ﬂow cytometric analysis. Brieﬂy, cells were ﬁxed in
90% ethanol/10% phosphate-buffered saline before incubation with
50mg/ml DNase-free RNase and 50mg/ml propidium iodide in staining
buffer (0.1% sodium citrate, 0.1% Triton X-100) for 30min at 371C, and
analysed by ﬂow cytometry (Cyan ADP; Dako, Ely, Cambridgeshire, UK).
Western blotting
Cells were incubated in lysis buffer (50mM Tris-HCl, pH 7.4, 150mM NaCl,
1% NP40, 0.5% sodium deoxycholate, 0.1% SDS, 1mM EDTA, ‘Complete’
protease inhibitors (Roche, Burgess Hill, UK) and ‘Phosphatase inhibitor
cocktail II’ (Merck Chemicals Ltd, Beeston, Nottingham, UK)) on ice for
15min. In all, 20mg of lysate was separated by SDS-PAGE and transferred
to nitrocellulose. Antibodies to cyclin D1 (DCS-6), cyclin D2 (M-20), CDK4
(C-22), CDK6 (C-21), pRb (C-15) and p27
Kip1 (C-19) were purchased from
Santa Cruz Biotechnology (Insight, Wembley, UK); phospho-pRB (Ser
807/811)
from New England Biolabs, Hitchin, UK; phospho-PKB (Ser
473) from
Invitrogen, Paisley, UK; Foxo 1, PKB, GAPDH, phospho-Foxo 1/4 and
phospho-Foxo3a from Cell Signalling Technologies, Danvers, MA, USA;
Foxo3a from Abcam, Cambridge, UK and actin (Ab-5) from BD Transduc-
tion Laboratories, Oxford, UK.
Blockade of PI3K/mTOR in vivo
All procedures involving the use and care of animals were performed in
accordance with the Animal Scientiﬁc Procedures Act (1986) and licensed
by the Home Ofﬁce. b2microglobulin null/NOD/SCID animals were housed
in speciﬁc pathogen-free conditions in individually ventilated cages
(Biozone, London, UK and Tecniplast, Buguggiate, Italy) and supplied with
sterile food, water and bedding. A total of 10
7 myeloma cells were
subcutaneously injected into the left ﬂank of 8-week-old unconditioned
animals. Animals were randomly assigned into control and treatment
groups. The dual PI3K/mTOR inhibitor NVP-BEZ235 (LC Laboratories,
Woburn, MA, USA)
16 was administered intraperitoneally daily at 40mg/kg
beginning 1 week after subcutaneous injection of myeloma cells. At the
end of study, tumours were excised, weighed and about 30mg were snap-
frozen and homogenized in lysis buffer. Total protein extracts were kept
at  201C until being processed for immunoblotting.
Statistics
Differences between conditions were analysed using paired or unpaired
two-tailed Student’s t-test, and are designated as means±s.d. or s.e.m.,
as appropriate. Differences were considered signiﬁcant for Po0.05.
RESULTS
Effects of PI3K/mTOR pathway Inhibition by PI-103 on growth of
myeloma cell lines depends on IgH translocation status
To determine the efﬁcacy of PI-103 in blocking MM cell
proliferation, we initially performed cell viability assays (MTS) in
selected HMCL with different underlying IgH translocations.
Figure 1a shows a dose-dependent decrease in the number of
viable MM1S and NCI-H929 cells cultured in the presence of PI-
103, with IC50 values of approximately 0.5 and 0.25mM, respec-
tively. In contrast, KMS12-BM cells were less sensitive, as an IC50
was not achieved with up to 2mM. NCI-H929 cells harbour the
t(4;14) IgH translocation that indirectly upregulates cyclin D2
mRNA, while MM1S cells carry a t(14;16) that upregulates cyclin D2
via the c-MAF transcription factor. KMS12-BM, on the other hand,
expresses cyclin D1 constitutively via t(11;14).
These data suggest that the response to PI3K blockade in MM
tumours may segregate with IgH translocation/D-type cyclin
group. To determine if this was more widely applicable, we
performed MTS assays on a panel of HMCL representing the three
major IgH translocation groups in MM (Figure 1b). We performed
these assays in both FCS and IGF-I, which is a major PI3K-
dependent, physiological mitogenic growth factor for MM.
These data conﬁrmed that t(11;14)-bearing MM cells are less
sensitive to PI-103 than those carrying a t(14;16) or t(4;14).
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when added to MM cells cultured in either FCS or IGF-I.
Cell cycle effects of dual PI3K/mTOR pathway inhibition in
myeloma cell lines is dependent on D-type cyclin/translocation
status
These data clearly demonstrated that PI-103 treatment led to a
reduction in cell number, and because this inhibitor has been
reported to act primarily by cytostatic rather than cytotoxic
mechanisms in other tumour types,
17 we investigated effects on
the cell cycle.
We started with a detailed analysis of both the PI-103-sensitive
cyclin D2-expressing MM1S line and the PI-103-resistant, cyclin
D1-expressing KMS12-BM line. Figure 2 shows the results of one
representative experiment in which cells were treated with PI-103
in the presence or absence of FCS, IGF-I or IL-6, another PI3K-
dependent MM growth factor. Both IGF-I and IL-6 increased the
proportion of MM1S cells entering the cell cycle (Figure 2a, upper
panel). After 24h, 43% of cells stimulated with IGF-I were in S and
G2/M phases, compared with 27% with IL-6, 21% with FCS and
11% in serum-free medium. PI-103 inhibited cell cycle progression
in all cases to the level of the serum-free control. Representative
cell cycle plots are shown in Figure 2b (upper panel). The
increased cell cycle entry observed with all three mitogenic stimuli
was accompanied by an upregulation of cyclin D2 as well as CDK4
and 6, resulting in increased phosphorylation of pRb at Ser807/
811, a CDK4/6-speciﬁc site (Figure 2c, left panel). Total pRb protein
was also increased, because phosphorylation of pRb by CDKs
releases pRb-mediated transcriptional repression of E2F transcrip-
tion factors, which induce the expression of genes required for
S-phase progression as well as pRb itself. In contrast, expression of
the CKI p27 was downregulated by mitogens. Meanwhile, PI-103
treatment inhibited the induction of cyclin--CDK complexes to
levels below that of the serum-free control and increased p27
expression, resulting in decreased pRb phosphorylation and cell
cycle exit.
In KMS12-BM, however, FCS, IGF-I and IL-6 failed to increase the
number of cells in S and G2/M phases compared with serum-free
medium (approximately 40% in all cases), and there was no
inhibition by PI-103 (Figures 2a and b, bottom panels). Interest-
ingly, IGF-I slightly decreased the number of KMS12-BM cells in S
phase, whereas PI-103 reversed this negative effect. In keeping
with the lack of effect of growth factors or PI-103 on cell cycle
progression, there was very little change in the expression of
cyclin D1 and associated cell cycle control proteins with the
different treatments (Figure 2c, right panel).
We conﬁrmed these effects of PI-103 on IGF-I-mediated cell
cycle entry/progression in a large panel of HMCL with known IgH
translocations (Figure 3). HMCL harbouring t(4;14) or t(14;16) were
more responsive to IGF-I and more sensitive to inhibition by PI-103
than HMCL with the t(11;14) translocation (Figure 3a). In HMCL
harbouring t(4;14) or t(14;16), IGF-I increased the percentage of
cells in S and G2/M phases from 24±3% to 31±3% (Po0.05) and
from 27±7% to 41±3% (Po0.05), respectively, whereas in
t(11;14)-bearing HMCL, cell cycle progression was unaffected by
Figure 1. Activity of PI-103 on growth of HMCL. (a) MM1S, NCI-H929 and KMS12-BM lines were treated with increasing concentrations
of PI-103 in standard growth medium (RPMI-1640 and 10% FCS). The relative number of viable cells was estimated by MTS assay at 24h
(mean±s.d. of triplicates in one representative experiment). (b) MTS viability assays were performed on a panel of HMCL treated with 1mM
PI-103 for 24h in the presence of 10% FCS (left panel) or 100ng/ml IGF-I (right panel). The key indicates the IgH translocation type for each
HMCL. Data shown are means±s.d. of triplicates in one representative experiment.
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Blood Cancer Journal & 2012 Macmillan Publishers LimitedFigure 2. Effect of PI-103 on cell cycle status in MM1S and KMS12-BM. Cells were cultured for 24h in either serum-free medium (RPMI-1640)
or RPMI-1640 plus 10% FCS, 100ng/ml IL-6 or 100ng/ml IGF-I±1mM PI-103 and analysed for DNA content by propidium iodide staining
and ﬂow cytometry. (a) The percentage of cells in each cell cycle phase with the different culture conditions is indicated by the shading
within the bars, according to the key. Data shown are from one of three representative experiments. (b) Representative cell cycle plots
indicating DNA content are shown for MM1S (upper panels) and KMS12-BM (lower panels). (c) Western blots for MM1S and KMS12-BM,
cultured for 24h as above, were probed with antibodies against cell cycle control proteins, as indicated. Anti-actin is shown as a loading
control.
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21±3% in t(4;14) cells (Po0.01) and to 20±4% in t(14;16) cells
(Po0.001), but was without effect on t(11;14) cells. The results of
these experiments suggest that the effect of PI-103 on viable MM
cell numbers may be mediated primarily by alterations in cell
cycle, consistent with other tumour types.
15
Consistent with the observed effects on the cell cycle,
PI-103 almost completely abolished the IGF-I-mediated increase
in cyclin D2 and phospho-pRb observed in t(4;14) or t(14;16)
HMCL, but had little or no effect on levels of cyclin D1 and
phospho-pRb in t(11;14) cells (Figure 3b). It should be noted, that
unlike primary MM cells,
7 some of the HMCL express both cyclins
D1 and D2.
The IGF-I/PI3K signalling pathway is functional in myeloma cells
with different IgH translocations
The relative insensitivity of t(11;14)-bearing MM cells to IGF-I and
PI-103 might relate to an inability of IGF-I to activate the PI3K
pathway in these cells. Thus, we examined the activation of key
Figure 3. Effect of PI-103 on cell cycle status in a panel of HMCL. Cells were cultured for 24h in either serum-free medium (RPMI-1640) with
or without 100ng/ml IGF-I±1mM PI-103 before being stained with propidium iodide to assess DNA content. (a) Upper panel: The percentage
of cycling cells (cells in S, G2 and M phases) for each IgH translocation group with each condition is indicated according to the key.
Data are mean±s.e.m., with n¼4 for the t(11;14) group, n¼4 for the t(14;16) group and n¼6 for the t(4;14) group. Lower panel:
Details of the HMCL tested are shown in the table below. (b) Representative western blots showing the inhibition of D-type cyclin expression
and CDK4/6-speciﬁc pRb phosphorylation by PI-103 in HMCL from different IgH translocation groups. Whole-cell lysates were prepared
from cells treated for 24h, as described above. Blots were probed with antibodies against cell cycle control proteins, as indicated. Anti-actin
is shown as a loading control. NB: The cyclin D2 antibody cross-reacts with cyclin D1, which appears as a slightly higher molecular weight
band. ND, not detected.
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tive HMCL. PKB is a major target of PI3K, mediating many of its
functions, including cell cycle regulation and protection from
apoptosis. Furthermore, PKB has been shown to positively
regulate D-type cyclins, in part, by phosphorylation and inactiva-
tion of the Foxo family of transcriptional repressors.
18- -21 Using an
antibody speciﬁc for the Ser
473-phosphorylated (active) form of
PKB, we observed robust activation of this pathway in response to
IGF-I in MM1S, NCI-H929 and KMS12-BM cell lines, representing all
three major IgH translocation groups (Figure 4). Phosphorylated
PKB and/or phospho-Foxo proteins were detected after 10--30min
in all cases, and remained elevated for up to 24h. Activation of
PKB preceded the upregulation of cyclin D2 that was evident by
3h in MM1S and by 6h in NCI-H929, whereas cyclin D1 was
unchanged in KMS12-BM. Importantly, PI-103 was able to
completely block PKB activation in all the three HMCL tested,
irrespective of the effect on D-type cyclin expression (Figure 4). In
addition, phosphorylation (and inactivation) of Foxo3a and/or
Foxo1/4 was also observed to be induced by IGF-I and inhibited by
PI-103 in all the three HMCL. These data suggest that cyclin D1
expression in t(11;14) MM cells is independent of PI3K activation.
In contrast, cyclin D2 induction in response to IGF-I in t(4;14) and
t(14;16) cells depends on PI3K and correlates with PKB activation.
In addition, these data suggest that the lack of responsiveness of
t(11;14) cells to serum deprivation is unlikely to be due to the
action of an autocrine growth factor loop, because most known
MM mitogenic growth factors are dependent on PI3K signalling.
PI-103 inhibits IGF-I-mediated proliferation in primary myeloma
cells bearing t(4;14) and t(14;16), and potentiates effects of anti-
myeloma agents
The results of our experiments with HMCL indicated that the
regulation of cyclin D1 in t(11;14)-bearing cells differs from that of
cyclin D2 in cells harbouring either t(4;14) or t(14;16). The relative
insensitivity of cyclin D1 levels to exogenous growth factors and
to PI3K blockade in t(11;14)-bearing cells was also reﬂected in a
lack of effect on other cell cycle proteins in these cells. We next
sought to determine if these effects of PI-103 were representative
of primary MM cells. CD138
þ-selected MM cells from 12 patients
with known IgH translocations (Figure 5) were cultured for 24h in
serum-free medium, either alone or in IGF-I±PI-103. Figure 5a
shows [
3H]-thymidine uptake in these cultures. Consistent with
our data derived from HMCL, t(11;14) positive primary MM cells
were unresponsive to IGF-I or PI-103 (left panel). Interestingly, case
no. 2 showed a slight decrease in [
3H]-thymidine uptake in the
presence of IGF-I, which was reversed by PI-103, an effect we have
also observed in some t(11;14) HMCL. In contrast, 6/8 cases with
either a t(4;14) or t(14;16) displayed increased [
3H]-thymidine
incorporation with IGF-I, which was inhibited by PI-103 (Figure 5a,
right panel). Notably, exposure to PI-103 led to a reduction in DNA
synthesis in every case, including the two cases that had little/no
response to IGF-I. The mean increase in [
3H]-thymidine uptake
induced by IGF-I in these tumour cells with IgH translocations
associated with cyclin D2 was 2.8-fold (Po0.02), which was
reduced to 0.8-fold in the presence of PI-103 (Po0.01).
Analysis of cell cycle control proteins in these patient samples
also conﬁrmed our data from HMCL. In MM cells from patients
harbouring t(14;16) or t(4;14), IGF-I increased expression of cyclin
D2 and phospho-pRb, a response that was substantially down-
regulated by PI-103 (Figure 5b, upper panel). In contrast, neither
IGF-I nor PI-103 had any signiﬁcant effect on cyclin D1 in MM cells
from t(11;14) cases (Figure 5b, lower panel).
We next asked whether cell cycle inhibition might be poten-
tiated when PI-103 is used in combination with common anti-
myeloma agents. Primary CD138
þ myeloma cells were treated
with PI-103 in the presence or absence of either melphalan,
bortezomib, dexamethasone or lenalidomide. We observed that
Figure 4. PI-103 blocks IGF-I-induced PI3K activation. MM1S,
NCI-H929 and KMS12-BM cells were washed with serum-free
medium (RPMI-1640) and stimulated with IGF-I (100 ng/ml) in
serum-free medium for between 10min and 24h in the presence or
absence of 1mM PI-103. Western blots were probed with antibodies
to PI3K phosphorylation target proteins and D-type cyclins, as
indicated. Equivalent loading is demonstrated by the level of total
PKB expression. NB: p-FOXO3a was not detected in KMS12-BM,
whereas total FOXO3a was not detected in NCI-H929 and FOXO1
detected only in KMS12-BM.
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CD138
þMM cells cultured for 24h in either serum-free medium (RPMI-1640) alone or with 100ng/ml IGF-I±1mM PI-103, as indicated. Each
data point represents the mean fold change in [
3H]-thymidine uptake in triplicate wells for individual patients. The mean fold change in
[
3H]-thymidine uptake for each group of patients for each culture condition is denoted by a horizontal bar. Data from cyclin D1-expressing
t(11;14) patients (n¼4) are shown in the left-hand panel; those from cyclin D2-expressing t(4;14) and t(14;16) patients are in the right-hand
panel. (b) Western blots of whole-cell lysates prepared from primary patient CD138
þ cells treated as described above, were probed with
antibodies against cell cycle control proteins, as indicated. Anti-actin is shown as a loading control. (c) The effect of PI-103 in combination
with chemotherapeutic drugs on [
3H]-thymidine uptake in two patients’ CD138
þ cells, treated as described. (d) The effect of PI-103 in
combination with chemotherapeutic drugs on the expression of cell cycle proteins in lysates prepared from cells from patient no. 8 treated
as described above. (e) Primary CD138
þ cells were treated with 100ng/ml IGF-I±1mM PI-103 in serum-free RPMI-1640 medium for 15min
and analysed for PKB activation by western blotting of whole-cell lysates. Equivalent loading is demonstrated by total PKB expression.
(f) Table showing details of patient samples used. BZ, bortezomib; Dex, dexamethasone; Len, lenalidomide; Mel, melphalan.
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of anti-myeloma agents in t(14;16)-bearing cells, but not in
cells harbouring t(11;14) (Figure 5c). Addition of PI-103 led to a
further reduction in [
3H]-thymidine uptake in MM cells from
patient no. 5 (with t(14;16)), when compared with the effect of
each anti-myeloma agent used alone. In contrast, there was no
signiﬁcant added effect of PI-103 with any of the anti-myeloma
agents when added to t(11;14) positive cells from patient no. 1.
Consistent with the potentiating effect on inhibition of DNA
synthesis in t(14;16)-bearing cells, PI-103 also produced a greater
reduction in phospho-pRb and cyclin D2 in MM cells from patient
no. 8 when used in combination with any of the chemother-
apeutic drugs compared with either agent used alone (Figure 5d).
Furthermore, as seen in HMCL, PI-103 substantially inhibits IGF-I-
mediated PKB phosphorylation in primary CD138
þ MM cells
(Figure 5e), suggesting a mechanism by which cyclin D2 and
subsequent cell cycle entry/progression are blocked by this agent.
Dual blockade of PI3K/mTOR with NVP-BEZ235 downregulates
cyclin D2 and CDK6 in vivo
To test the effect of combined PI3K/mTOR blockade in vivo,w e
used the orally bioavailable inhibitor NVP-BEZ235.
16 We estab-
lished subcutaneous tumours by injecting 10
7 cells from the HMCL
JIM-1 that bears t(4;14) into the ﬂank of unconditioned b2micro-
globulin null/NOD/SCID animals. Initial experiments had estab-
lished the time course of tumour growth, and six animals were
treated daily with intraperitoneal injections of NVP-BEZ235 once
tumours were palpable. A control group of animals (n¼5) were
injected with vehicle only. Animals were killed when the largest
tumours had reached 1cm at the longest diameter (4 weeks from
tumour cell injection) and tumour weights were recorded. There
was a trend to smaller tumours from animals treated with NVP-
BEZ235 (Figure 6a), although this did not reach signiﬁcance in this
small series of animals. Importantly, there was a signiﬁcant
downregulation of pAkt, cyclin D2 and CDK6 in these tumours,
when compared with tumours from control animals treated with
vehicle (Figures 6b and c).
DISCUSSION
The major new ﬁnding reported here is that the effect of PI3K/
mTOR blockade on cell cycle progression in MM cells is critically
dependent on the underlying mode of cyclin D dysregulation,
which in turn is dictated by IgH translocation status. The PI3K
pathway is a major downstream signalling pathway utilised by the
most important growth/survival factors for MM. Such factors,
thought to have a role in mediating the protective effect of the
myeloma BM microenvironment include IGF-I, IL-6, vascular
endothelial growth factor, ﬁbroblast growth factor, hepatocyte
growth factor, APRIL and BAFF.
22,23 We and others have shown
previously that in addition to its well-characterised role in
mediating cell survival, PI3K is essential for mediating cell cycle
entry and expression of D-type cyclins in B-lineage cells. Notably,
mice that are genetically deﬁcient in Class I PI3K are deﬁcient
in B-cell development and activation, and are unable to induce
cyclin D2 normally in response to mitogens.
11,24 Furthermore,
PI3K-knockout mice are phenotypically similar to mice lacking
cyclin D2.
11,25
Using a panel of HMCL with different IgH translocations, we
observed that cells bearing t(4;14) or t(14;16) were more sensitive
to PI-103-mediated growth inhibition when compared with
t(11;14)-bearing cells. This differential sensitivity to PI-103 was
apparent when cells were grown in their standard 10% FCS
medium or in IGF-I alone. Further analysis revealed that these
differences are largely due to differential effects on the cell cycle,
with PI-103 treatment leading to cell cycle arrest in the t(4;14)- or
t(14;16)-bearing cells, but not in t(11;14)-bearing cells. The cell
cycle arrest observed in t(4;14) and t(14;16) cells was mediated by
a decrease in cyclin D2, CDK 4 and CDK6 expression and an
increase in levels of p27, concomitant with decreased CDK4/6-
speciﬁc pRb phosphorylation and total pRb. These changes are
similar to those observed in normal B lymphocytes undergoing
cell cycle arrest due to serum deprivation or PI3K inhibition,
24,26,27
where decreased cyclin D2-CDK4/6 complexes are unable to
titrate p27 (a CIP/WAF family CKI) away from cyclin E/CDK2
complexes, leading to further dephosphorylation of pRb and
Figure 6. Effect of dual blockade of PI3K/mTORin vivo. MM tumours
were established in unconditioned b2microglobulin null/NOD/SCID
animals by subcutaneous injection of JIM-1 cells (10
7/animal).
Animals were randomly assigned to treatment (six) and control (ﬁve)
groups; treatment groups received BEZ235 as detailed in Materials
and methods, whereas control animals received injections of diluent
only. Tumours were excised at 4 weeks, weighed and lysates probed
for proteins as detailed below. (a) BEZ235 treated animals had
smaller tumours than those from the control group. (b) Whole-cell
lysates were prepared from about 30mg of excised tumours. Blots
were probed with antibodies against proteins as indicated. Anti-
GAPDH is shown as a loading control. (c) Protein expression was
quantiﬁed using Image J 1.43 and results are expressed as a ratio to
control. *Po0.05, **Po0.01.
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also downregulated as it is itself an E2F-regulated gene. In
contrast to cyclin D2-expressing cells, and in keeping with the lack
of cell cycle inhibition, there were little or no changes observed in
G1-phase cell cycle control proteins in t(11;14) cells treated with
PI-103.
Here, we show, for the ﬁrst time, that PI3K inhibition modulates
cyclin D2 protein levels in primary CD138þ MM cells. We also
conﬁrm, in a larger cohort of patients, our earlier ﬁndings that, in
primary MM cells bearing t(4;14) or t(14;16), cyclin D2 is
functionally upregulated by IGF-1, unlike cyclin D1 expressed via
a t(11;14), which is unresponsive to IGF-1. IGF-I stimulation
increased protein levels of cyclin D2 as well as CDK4/6-speciﬁc
pRb phosphorylation in MM cells from patients harbouring t(4;14)
or t(14;16). We have recently reported that APRIL modulates cyclin
D2 and cell cycle proteins to induce cell cycle progression in
t(4;14)- and t(14;16)-bearing primary MM cells.
8 Such cell cycle
responses to APRIL were absent in cyclin D1MM cells. In t(4;14) or
t(14;16) cells, cyclin D2 is upregulated indirectly by overexpression
of the MMSET/FGFR3 proteins or by the c-MAF transcription
factors, which may themselves be subjected to regulation by
mitogens. Thus, it is unsurprising that cyclin D2 which is under the
control of its natural, growth-factor responsive promoter is
sensitive to PI3K inhibition, because PI3K is known to be a major
regulator of this protein in haematopoietic cells. MM cells carrying
a t(11;14), however, express cyclin D1 constitutively by the strong
IgH enhancer elements, thus rendering it independent of
mitogenic signalling. What is perhaps surprising is that other cell
cycle proteins, such as CDK4/6, total pRb and p27 are also
unaffected by mitogens and/or PI3K inhibition in t(11;14) cells,
because expression of these proteins should remain under normal
physiological regulation. This is especially pertinent for p27, which
is known to be regulated by PI3K.
28,29 It is possible that in the
presence of excess cyclin D1, the cyclin D1-CDK4/6-p27 complexes
are stably maintained and/or exert feedback signalling that
overrides regulation by mitogenic withdrawal or PI3K inhibition.
Alternatively, t(11;14) MM cells may evolve in a mitogen-
independent manner, so that upregulation of cyclin D1 (an early,
premalignant event) is associated with later mutations
that maintain constitutive expression of CDK4/6-p27 complexes
independently of PI3K activity. However, because most primary
t(11;14) MM cells are not constitutively in cycle,
30 there must
be as yet unrecognised signals that regulate their cell cycle entry
in vivo.
Although this study has focussed on MM cells harbouring an
IgH translocation, approximately 50% of MM cases are char-
acterised by hyperdiploidy and an absence of an IgH translocation.
It is technically challenging to investigate the mechanisms of cell
cycle control in this group, because they are not adequately
represented by HMCL. However, recent data from our laboratory,
utilising an improved culture method for primary MM cells, have
demonstrated that in the hyperdiploid group, cyclin D2-expres-
sing tumours are more sensitive to growth factors than cyclin D1-
expressing tumours, but are less responsive when compared with
cyclin D2-expressing cases harbouring t(14;16) or t(4;14).
8 This
study has focussed on cell cycle regulation, however, other work
from our group has shown that dependence on survival signalling
from the PI3K pathway is also dictated by IgH translocation
status.
31 These data support the hypothesis that t(11;14) cells
clonally evolve in a manner that makes them relatively refractory
to signals emanating from these classical myeloma growth/
survival factors when compared with those harbouring IgH
translocations targeting cyclin D2.
The relative insensitivity of t(11;14) cells to PI-103 could be
explained by a functionally inactive PI3K pathway. Alternatively,
they might have a hyper-activated pathway (for example, due to
mutation of PI3K subunits) refractory to enzymatic inhibition.
Neither of these explanations, however, is borne out by our
observations on the activation of key PI3K signalling intermedi-
ates. When we compared MM cells representing the three major
IgH translocation groups, we found no differences in IGF-I-induced
activation of PKB. Furthermore, PI-103 abrogation of PKB
phosphorylation was equally apparent in t(11;14) cells compared
with t(4;14) or t(14;16) cells. Thus, the differential impact of PI3K/
mTOR blockade on cell cycle progression between cyclin D2-
expressing t(4;14) or t(14;16) and cyclin D1-expressing t(11;14) MM
tumours may be due to the composition and activity of cyclin
D---CDK complexes, and their regulation by proteolytic mechanisms.
Differential sensitivity to PKB inhibition has been observed by
Zollinger et al.,
32 who attributed this to differences in constitutive
PKB phosphorylation both in HMCL and primary MM cells.
Although the emphasis was on apoptosis rather than cell cycle
regulation, the HMCL shown to be sensitive to PKB inhibition were
OPM2 and MM1S, which are t(4;14) and t(14;16) positive,
respectively, whereas the t(11;14) HMCL, U266 was insensitive.
These, and our ﬁndings reported here, raise the possibility that
IgH/cyclin D status may dictate patients’ response to therapies
aimed at inhibition of PKB and other targets downstream of PI3K.
Several genetic abnormalities have been associated with in-
creased PKB activation, including mono-allelic deletion of PTEN,
present in approximately 5% of BM MM cells, and up to 20% in
plasma cell leukaemias and HMCL.
33 However, PTEN mutations
were found to be absent in most MM cells with constitutively
activated PKB, while ‘hotspot’ mutations in PIK3CA (which codes
for the p110 alpha catalytic subunit of PI3K) and PKB identiﬁed in
a variety of other tumours were not found in MM,
34 suggesting
either that other genetic abnormalities are responsible or that the
activation is due to increased growth factor responsiveness.
We used primary MM cells to test whether the inhibitory effect
of PI-103 on cell cycle progression would enhance the activity of
anti-MM agents. We observed, in primary t(14;16)-bearing MM
cells, that the addition of PI-103 to melphalan, bortezomib,
dexamethasone or lenalidomide resulted in a greater inhibition of
DNA synthesis and greater reduction in levels of cyclin D2 and
CDK4-/6-phosphorylated pRb than observed with either drug
alone. In contrast, in t(11;14)-bearing cells, no such potentiating
effect was observed. These data indicate that combination
therapies utilising PI3K/mTOR inhibitors would be particularly
effective in those patients with IgH translocations that target
cyclin D2. The importance of dual inhibition of both PI3K and
mTOR pathways has been recently recognized.
14 Although PI-103
itself is unlikely to progress to clinical development because of its
limited solubility and extensive metabolism, several pharmacolo-
gically optimised PI3K/mTOR inhibitors are in development. One
such agent, NVP-BEZ235, was also recently shown to inhibit MM
cell growth and proliferation and exhibit synergy with anti-MM
drugs in two independent studies.
16,35 McMillin et al.,
35 in their
work on HMCL, noted that there was varying sensitivity to the
effect of this PI3K/mTOR inhibitor, but did not report any
correlation with genetic lesion. Using NVP-BEZ235, we demon-
strate that dual blockade of PI3K/mTOR downregulates cyclin D2
and CDK6 in vivo, leading to an attenuation of tumour growth in
MM cells bearing t(4;14).
In summary, we report that the effect of PI3K/mTOR inhibition
on cell cycle progression in MM cells segregates with IgH/D-type
cyclin status. Importantly, tumour cells from patient subgroups
with inferior outcomes, and characterised by higher proliferative
behaviour, including responses to mitogens, are particularly sensitive
to PI3K pathway blockade. These tumour cells express cyclin D2 in
conjunction with the t(4;14) or t(14;16), whereas tumours with a
different genetic background, that is, expressing cyclin D1 with
t(11;14), that confers a neutral prognosis, are largely insensitive.
Our ﬁndings provide the rationale for the incorporation of dual
PI3K/mTOR inhibitors in treatment strategies aimed at patients
with t(4;14) or t(14;16), and set the scene for future mechanistic
studies on cell cycle regulation in these distinct subtypes of MM.
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